Dimethyl fumarate treatment alters NK cell function in multiple sclerosis

Eur J Immunol. 2018 Feb;48(2):380-383. doi: 10.1002/eji.201747277. Epub 2017 Dec 15.

Abstract

Dimethyl fumarate (DMF) treatment in multiple sclerosis (MS) increased the proportion of immunoregulatory CD56bright NK cells and this change was proportional to reductions in CD8+ memory T cells. DMF and monomethyl fumarate (MMF) treatment in vitro had directs effects on NK cells and promoted degranulation and cytotoxicity.

Keywords: CD155; CD56; Dimethyl fumarate; Multiple Sclerosis; NK cells.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD56 Antigen / metabolism
  • CD8-Positive T-Lymphocytes / drug effects
  • CD8-Positive T-Lymphocytes / immunology*
  • Cell Degranulation
  • Cells, Cultured
  • Cohort Studies
  • Cytotoxicity Tests, Immunologic
  • Dimethyl Fumarate / pharmacology*
  • Dimethyl Fumarate / therapeutic use
  • Follow-Up Studies
  • Humans
  • Immunologic Memory
  • Immunomodulation
  • Immunosuppressive Agents / pharmacology*
  • Immunosuppressive Agents / therapeutic use
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / immunology*
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology

Substances

  • CD56 Antigen
  • Immunosuppressive Agents
  • Dimethyl Fumarate